A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Néboa ZozayaMaria Iciar Arrizubieta BasterrecheaElena BolloIván CastellvíJaime EspínNorberto OrtegoJosé Luis Poveda-AndrésJosé Antonio Rodríguez PortalAgustín RiveroJosé Antonio Marcos-RodríguezLuis Verde

Published in: International journal of technology assessment in health care (2022)

Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain.

Keyphrases

interstitial lung disease
idiopathic pulmonary fibrosis
systemic sclerosis
rheumatoid arthritis
clinical trial
decision making
study protocol